Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.4 (1y: -32%)
Market Cap 169.7 M P/E(ttm)
Enterprise Value 85.59 M P/B 2.60
FOLD- NAS (USA)
Amicus Therapeutics, Inc.
Not Rated
Top Ranked Predictable Companies
$3.40
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 142.212
FOLD's Cash to Debt is ranked higher than
54% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 46.63 vs. FOLD: 142.212 )
FOLD' s 10-Year Cash to Debt Range
Min: 20.05   Max: 142.21
Current: 142.21
20.05
142.21
Equity to Asset 0.629
FOLD's Equity to Asset is ranked higher than
62% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. FOLD: 0.629 )
FOLD' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.84
Current: 0.63
0.42
0.84
Interest Coverage No Debt
FOLD's Interest Coverage is ranked higher than
67% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 37.90 vs. FOLD: No Debt )
FOLD' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: -1.09
M-Score: 9.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -287.50
FOLD's Operating margin (%) is ranked lower than
75% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -31.50 vs. FOLD: -287.50 )
FOLD' s 10-Year Operating margin (%) Range
Min: -6056.2   Max: -11.4
Current: -287.5
-6056.2
-11.4
Net-margin (%) -265
FOLD's Net-margin (%) is ranked lower than
73% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -29.90 vs. FOLD: -265 )
FOLD' s 10-Year Net-margin (%) Range
Min: -5958.4   Max: -10.2
Current: -265
-5958.4
-10.2
ROE (%) -70.5
FOLD's ROE (%) is ranked lower than
80% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. FOLD: -70.5 )
FOLD' s 10-Year ROE (%) Range
Min: -150.1   Max: -9.1
Current: -70.5
-150.1
-9.1
ROA (%) -44.3
FOLD's ROA (%) is ranked lower than
75% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. FOLD: -44.3 )
FOLD' s 10-Year ROA (%) Range
Min: -63.6   Max: -7.7
Current: -44.3
-63.6
-7.7
ROC (Joel Greenblatt) (%) -3152.50
FOLD's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. FOLD: -3152.50 )
FOLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3152.5   Max: -3152.5
Current: -3152.5
Revenue Growth (%) -38.7
FOLD's Revenue Growth (%) is ranked lower than
91% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. FOLD: -38.7 )
FOLD' s 10-Year Revenue Growth (%) Range
Min: -38.7   Max: -1.9
Current: -38.7
-38.7
-1.9
EBITDA Growth (%) 48.5
FOLD's EBITDA Growth (%) is ranked higher than
98% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. FOLD: 48.5 )
FOLD' s 10-Year EBITDA Growth (%) Range
Min: -12.9   Max: 48.5
Current: 48.5
-12.9
48.5
EPS Growth (%) 38.6
FOLD's EPS Growth (%) is ranked higher than
97% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. FOLD: 38.6 )
FOLD' s 10-Year EPS Growth (%) Range
Min: -10.9   Max: 38.6
Current: 38.6
-10.9
38.6
ยป FOLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

FOLD Guru Trades in Q2 2012

RS Investment Management 959,747 sh (+19.23%)
Jim Simons 68,000 sh (-59.04%)
» More
Q3 2012

FOLD Guru Trades in Q3 2012

Steven Cohen 100,000 sh (New)
RS Investment Management 1,017,537 sh (+6.02%)
Jim Simons Sold Out
» More
Q4 2012

FOLD Guru Trades in Q4 2012

RS Investment Management 2,051,727 sh (+101.64%)
Steven Cohen Sold Out
» More
Q1 2013

FOLD Guru Trades in Q1 2013

Jim Simons 67,843 sh (New)
RS Investment Management 2,599,787 sh (+26.71%)
» More
» Details

Insider Trades

Latest Guru Trades with FOLD



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 2.60
FOLD's P/B is ranked higher than
64% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. FOLD: 2.60 )
FOLD' s 10-Year P/B Range
Min: 0.64   Max: 7.98
Current: 2.6
0.64
7.98
P/S 15.50
FOLD's P/S is ranked lower than
64% of the 391 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. FOLD: 15.50 )
FOLD' s 10-Year P/S Range
Min: 0.71   Max: 217.67
Current: 15.5
0.71
217.67
EV-to-EBIT 6.9
FOLD's EV-to-EBIT is ranked lower than
92% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. FOLD: 6.9 )
FOLD' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 0.8
Current: 6.9
0.1
0.8

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 2.9
FOLD's Price/Net Cash is ranked higher than
83% of the 189 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. FOLD: 2.9 )
FOLD' s 10-Year Price/Net Cash Range
Min: 1.4   Max: 7.6
Current: 2.9
1.4
7.6
Price/Net Current Asset Value 48.6
FOLD's Price/Net Current Asset Value is ranked lower than
56% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. FOLD: 48.6 )
FOLD' s 10-Year Price/Net Current Asset Value Range
Min: 19.2   Max: 61.4
Current: 48.6
19.2
61.4
Price/Tangible Book 2.4
FOLD's Price/Tangible Book is ranked higher than
75% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. FOLD: 2.4 )
FOLD' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 4
Current: 2.4
1.2
4
Price/Median PS Value 0.6
FOLD's Price/Median PS Value is ranked higher than
83% of the 345 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. FOLD: 0.6 )
FOLD' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 22.4
Current: 0.6
0.2
22.4

Business Description

Amicus Therapeutics, Inc. was incorporated on February 4, 2002 in Delaware. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. The Company is focused on the development of pharmacological chaperones as monotherapies and in combination with enzyme replacement therapy (ERT), the current standard of treatment for Fabry and other lysosomal storage diseases. In 2012, it is advancing two monotherapy programs for genetic diseases: Migalastat HCl for patients with Fabry disease identified as having alpha-galactosidase A (alpha-Gal A) mutations amenable to chaperone therapy, and AT3375 for Parkinson's disease in Gaucher disease carriers and potentially the broader Parkinson's population. Its pharmacological chaperone-ERT combination programs for 2012 include: Migalastat HCl co-administered with ERT for patients with Fabry disease receiving ERT treatment with any genetic mutation, AT2220 (duvoglustat HCl) co-administered with ERT for Pompe disease, AT3375 and afegostat tartrate co-administered with ERT for Gaucher disease, and Several new, undisclosed pharmacological chaperone programs focused on the combination of chaperones with ERTs for additional lysosomal storage diseases. The Company's novel approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein; increasing the stability of the protein and helping it fold into the correct three-dimensional shape. Its lead product candidate, migalastat HCl for Fabry disease, is in late Phase 3 development. It is developing and commercializing migalastat HCl with an affiliate of GlaxoSmithKline PLC (GSK) pursuant to a License and Collaboration Agreement entered into in October 2010. Its partnership with GSK allows it to utilize GSK's significant expertise in clinical, regulatory, commercial and manufacturing matters in the development of migalastat HCl. In addition, it is conducting another Phase 2 co-administration study evaluating its pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with ERT in Pompe patients. Unlike migalastat HCl, it owns rights to the development of AT2220. In addition to its patents and trade secrets, The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design and AMICUS THERAPEUTICS. Its competitors include Sanofi Aventis, Shire, Actelion, Ltd. and Protalix Biotherapeutics. The Company's product candidates, including migalastat HCl, and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subje
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:AM6.Germany
ยป More Articles for FOLD

Headlines

Articles On GuruFocus.com
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial